Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study.

Health science reports·2026
Same author

Comparison of Diabetic Nephropathy Markers in Diabetic Patients With Insomnia Before and After Potassium and Magnesium Supplementation: A Randomized Controlled Trial.

Health science reports·2026
Same author

Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: Third Edition".

International journal of molecular sciences·2025
Same author

The Involvement of the Peptidergic Systems in Breast Cancer Development.

Cancers·2025
Same author

Closing Editorial for the Special Issue: "Advanced Treatment of Schizophrenia".

Biomedicines·2025
Same author

A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast Cancer.

International journal of molecular sciences·2025

Related Experiment Video

Updated: May 14, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Targeting Peptidergic Systems for Melanoma Treatment.

Manuel L Sánchez1, Riffat Mehboob2,3, Rafael Coveñas1,4

  • 1Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla and León (INCYL), University of Salamanca, c/ Pintor Fernando Gallego 1, 37007 Salamanca, Spain.

Cancers
|May 13, 2026
PubMed
Summary

Targeting peptidergic systems offers significant potential for novel melanoma treatments. Exploring these systems, alone or with existing therapies, could improve outcomes for this aggressive skin cancer.

Keywords:
anticancer peptidesmelanomaoncogenic peptidespeptide receptor antagonistspeptidergic systemspeptides

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 14, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Melanoma is an aggressive skin cancer with poor survival rates in advanced stages.
  • Peptidergic systems play a complex role in melanoma development and progression.
  • New therapeutic strategies are urgently needed, especially for younger populations.

Purpose of the Study:

  • To review the potential of targeting peptidergic systems for melanoma treatment.
  • To discuss the role of oncogenic and anti-melanoma peptides and their receptors.
  • To explore combination therapies involving peptidergic systems and standard treatments.

Main Methods:

  • Review of literature on peptidergic systems in melanoma.
  • Analysis of oncogenic/anti-melanoma peptides and peptide receptors.
  • Discussion of current and novel anti-melanoma strategies.

Main Results:

  • Peptides can exert oncogenic, anti-melanoma, or dual effects, highlighting functional complexity.
  • Numerous strategies targeting peptidergic systems are under development, including antibodies, antagonists, agonists, and vaccines.
  • Peptide receptor expression is crucial for diagnosis, risk assessment, and targeted therapies.

Conclusions:

  • Targeting peptidergic systems presents a promising avenue for melanoma therapy.
  • Combination therapies involving peptidergic systems and standard treatments warrant further investigation.
  • Understanding peptidergic systems can lead to more specific and effective melanoma treatments.